Supriya Lifescience Ltd., a leading cGMP-compliant manufacturer of Active Pharmaceutical Ingredients (APIs), has taken a significant step toward sustainability with the inauguration of a state-of-the-art 5 MWp solar power facility in Nanded District, Maharashtra. The project was inaugurated by Dr. Satish Wagh, Chairman of Supriya Lifescience, reaffirming the company’s commitment to renewable energy and environmental responsibility.
Commitment to a Greener Future
This initiative is part of Supriya Lifescience’s ongoing efforts to reduce its carbon footprint and integrate sustainable energy solutions into its operations. With this latest addition, the company’s total installed solar capacity has now reached 9.85 MWp, including the existing 4.85 MWp solar projects in Solapur District, Maharashtra. These projects align with India’s climate change goals, reducing reliance on fossil fuels and supporting a cleaner, more sustainable energy ecosystem.
Dr. Satish Wagh, Chairman & Whole-Time Director of Supriya Lifescience Ltd., stated:
“Embracing renewable energy is not just a strategic business decision but a commitment to a greener future. Our solar power investments are integral to our vision of sustainable growth and reducing environmental impact.”
Collaboration for Renewable Energy Excellence
The latest solar project was successfully executed in partnership with Enrich Energy Pvt. Ltd., a leader in renewable energy solutions. By integrating solar energy into its operations, Supriya Lifescience is reinforcing its commitment to sustainability while ensuring greater energy efficiency in pharmaceutical manufacturing.
As a pioneering force in the pharmaceutical industry, Supriya Lifescience continues to align its operations with global best practices in energy conservation. By prioritizing solar energy, the company is actively contributing to India’s ambitious renewable energy targets and reducing greenhouse gas emissions.
About Supriya Lifescience Ltd.
Founded in 1987, Supriya Lifescience Ltd. is a globally recognized producer of Active Pharmaceutical Ingredients (APIs). The company operates a state-of-the-art manufacturing facility in Khed, District Ratnagiri, and is headquartered in Mumbai, India.
With certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA, the company upholds the highest standards of quality and compliance. Its globally certified facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are backed by robust R&D, eight active CEPs, and fourteen active USDMFs.
Guided by EHS requirements and ethical business principles, Supriya Lifescience focuses on developing high-quality intermediates and APIs for both innovators and generic pharmaceutical firms. The company also collaborates with partners as a Contract Manufacturing Organization (CMO), further strengthening its industry leadership.
